

<p>(51) International Patent Classification ⁶ : C07J 71/00, A61K 31/58</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/32763 (43) International Publication Date: 30 July 1998 (30.07.98)</p>
<p>(21) International Application Number: PCT/US98/01846 (22) International Filing Date: 29 January 1998 (29.01.98) (30) Priority Data: 08/794,229 29 January 1997 (29.01.97) US (71) Applicant: SRI INTERNATIONAL [US/US]; 333 Ravenswood Avenue, Menlo Park, CA 94025 (US). (72) Inventors: TANABE, Masato; 972 Moreno, Palo Alto, CA 94303 (US). PETERS, Richard, H.; 365 Springpark Circle, San Jose, CA 95136 (US). CHAO, Wan-Ru; 1510 Oriole Avenue, Sunnyvale, CA 94087 (US). SHIGENO, Kazuhiko; 555 W. Middlefield Road H-205, Mountain View, CA 94043 (US). (74) Agents: REED, Dianne, E.; Bozicevic & Reed LLP, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US) et al.</p>		<p>(81) Designated States: CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: STEROID INHIBITORS OF ESTRONE SULFATASE, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE</p>		
<p>(57) Abstract</p> <p>Novel compounds useful as inhibitors of estrone sulfatase are provided. The compounds have structural formula (I), wherein X and Y, or Y and Z, form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring, and the other various substituents are as defined herein. Also provided are pharmaceutical compositions and methods for using the compounds of formula (I) to inhibit the enzymatic activity of estrone sulfatase and to treat estrogen-dependent disorders.</p> <div data-bbox="912 1129 1440 1434"> <p style="text-align: right;">(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

STEROID INHIBITORS OF ESTRONE SULFATASE, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE


TECHNICAL FIELD

5 The present invention relates generally to steroid hormones, and more specifically relates to novel steroids which are inhibitors of the enzyme estrone sulfatase. The invention additionally relates to methods for inhibiting estrone sulfatase activity, to treatment of disorders that are estrogen-dependent, i.e., are estrogen-induced or estrogen-stimulated, and to pharmaceutical compositions containing one or more of the novel compounds.

BACKGROUND

10 Breast cancer is one of the most prevalent types of cancer, and epidemiological and clinical studies have shown that approximately one-third of breast tumors are estrogen-dependent. This means that estrogens are required for the growth of such breast tumors in both premenopausal and
15 postmenopausal patients. In postmenopausal women, in whom breast cancer most commonly occurs, breast tumor concentrations of estrone and estradiol are considerably higher than blood estrogen levels. Although retention of estrogens in breast tumors by high-affinity binding proteins contributes to the level of estrogens in tumors, estrogen concentrations in the breast are higher than plasma levels in breast cancer patients regardless of whether their tumors are estrogen receptor-positive (ER+) or
20 receptor-negative (ER-). *In situ* formation of estrogen from estrogen biosynthetic precursors within tumors is now known to make a major contribution to the estrogen content of breast tumors.

 The enzymes required for estradiol biosynthesis (i.e., aromatase, 17 β -hydroxy-steroid dehydrogenase, and estrone sulfatase) are present in normal and malignant breast tissues. Blood concentrations of estrone sulfate are 8- to 10-fold greater than those of unconjugated free estrone, and
25 breast tissue concentrations of estrone sulfatase activity, the enzyme responsible for the conversion of estrone sulfate to estrone, are a thousand-fold higher than those of aromatase activity. Together, these findings suggest that estrone sulfatase plays a key role in regulating the formation of estrogens within breast tumors, particularly in postmenopausal women. *See, e.g.*: Pasqualini et al., Ann. N.Y. Acad. Sci. 464:106-116 (1986); Santner et al., J. Clin. Endocrinol. Metabol. 59(1):29-33 (1984); Evans et al.,
30 J. Steroid Biochem. Mol. Biol. 39:493-499 (1991); Pasqualini et al., J. Steroid Biochem. Mol. Biol. 41(308):323-329 (1992); Vignon et al., Endocrinology 106(4):1079-1086 (1980); and Santner et al., Int. J. Cancer 54:119-124 (1993).



There is additional evidence of the relative significance of the aromatase pathway and the estrone sulfatase pathway in providing sufficient estrogen to sustain tumor growth. In postmenopausal women, the levels of estradiol in breast tumor tissues are 10 to 40 times higher than in plasma and are similar to those in premenopausal women, even though plasma estrogen levels are much lower after the menopause. This concentration gradient is not entirely due to estradiol uptake and binding to estrogen receptors, since tissue estradiol levels correlate poorly with estrogen receptor levels.

In situ production of estradiol, through either the aromatase or the estrone sulfatase pathway, could affect this gradient. The level of estrone sulfate present in the serum of postmenopausal women is 10 times higher than the level of free estrogens (Prost et al., Cancer Res. 44:661-664 (1984)). Serum estrone sulfate levels are also higher in postmenopausal women with breast cancer than in normal postmenopausal women (Purohit et al., Int. J. Cancer 50:901-905 (1992)). Also, sulfatase levels in tumors are much higher than aromatase levels (Pasqualini et al., J. Steroid Biochem. 34(1-6):155-163 (1989); Adams et al., Cancer Res. 39:5124-5126 (1979)). The absolute levels of aromatase activity in tumors are relatively low, ranging from 5 to 80 pmol/g protein/h. Bradlow (Bradlow et al., Cancer Res. (Suppl.) 42:3382s-3386s (1982)) and others consider this degree of tumor aromatase activity too low for a biologically meaningful level of estradiol to be synthesized locally within the tumor.

Quantitative information on the local production of estrogen shows that the sulfatase activity in breast tumors is more than 10 times the aromatase activity. When sulfatase and aromatase activity in human tumors were compared at physiological levels of substrate, sulfatase produced 2.8 pmol estrone/g protein/h while aromatase produced only 0.27 pmol/g protein/h. Consequently, estrone sulfate represents one of the most important precursors for tissue production of estradiol, and estrone sulfatase is a quantitatively more important local route for estrogen production than aromatase.

To date, little work has been done in the development of estrone sulfatase inhibitors. Li et al., Steroids 60 (March 1995), at pages 299-306, evaluate several compounds as potential inhibitors of human placental steryl sulfatase, but do not identify any highly potent estrone sulfatase inhibitors. Similarly, Duncan et al., Cancer Research 53:298-303 (1993), evaluate a potential estrone sulfatase inhibitor, estrone-3-methylthiophosphonate, but conclude that the experimental work done with that compound would hopefully lead to development of "more efficient" inhibitors of the enzyme.

Accordingly, the present invention is directed to novel compounds that are extremely effective estrone sulfatase inhibitors. The invention thus represents a significant advance in the art, particularly in the treatment of breast cancer and other diseases and conditions that are potentiated by the presence of estrogens.

In addition to the aforementioned references, the following pertain to one or more aspects of the invention and as much may be of background interest to those skilled in the art: Howarth et al., J.

Med. Chem. 37:219-221 (1994) and PCT Publication No. WO93/05064 relate to estrone sulfamates as inhibitors of steroid sulfatases, with Howarth et al. specifically focused on inhibition of estrone sulfatase; and U.S. Patent Nos. 3,033,860 to Kuehne and 4,297,350 to Babcock et al., which describe steroids having an additional cyclic structure adjacent to the "A" ring.

No art of which applicants are aware, however, describe compounds as provided herein, to inhibit estrone sulfatase or for any other purpose. To the best of applicants' knowledge, then, the compounds and methods of the invention are previously unknown and completely unsuggested by the art.

SUMMARY OF THE INVENTION

Accordingly, it is a primary object of the invention to address the above-mentioned need in the art by providing novel compounds useful as inhibitors of estrone sulfatase.


It is another object of the invention to provide a method for inhibiting estrone sulfatase activity using the novel compounds.

It is still another object of the invention to provide a method for treating an individual with a disorder that is estrogen-dependent, i.e., an estrogen-induced or estrogen-stimulated condition or disease, by administering to the individual an effective estrone sulfatase inhibiting amount of a novel compound as provided herein, or a pharmaceutically acceptable salt thereof.

It is a further object of the invention to provide a pharmaceutical composition for treating an individual with a disorder that is estrogen-dependent, the composition comprising a pharmaceutically acceptable carrier and an effective estrone sulfatase inhibiting amount of a novel compound as provided herein or a pharmaceutically acceptable salt thereof.

Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following, or may be learned by practice of the invention.

In one embodiment, the invention relates to novel compounds having the structure of Formula (I)



wherein:

n is 1 or 2;

R¹ and R² are different, and are selected from the group consisting of hydrogen, lower alkyl, lower alkynyl, and OR⁶ where R⁶ is hydrogen, lower alkyl or

5 -(CO)-R⁷ where R⁷ is lower alkyl, or wherein R¹ and R² together form =O, =S, or =C(R⁸R⁹) in which R⁸ and R⁹ are independently selected from the group consisting of hydrogen, -CHO, lower alkyl, and cyano, or together form a =CH₂ substituent;

R³ is hydrogen, halogen or lower alkyl, or, when the dotted line at q₁ indicates the presence of a double bond, is CH₂;

10 R⁴ is selected from the group consisting of hydrogen and lower alkyl;

R⁵ is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, lower alkenyl, lower alkoxy, and aryl, or when the dotted line at q₂ indicates the presence of a double bond, is CH₂; and either

15 X and Y are linked to form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring, if dihydro-oxathiazine, having a substituent R¹⁰ on the carbon atom *ortho* to the A ring, wherein R¹⁰ is hydrogen, lower alkyl, lower alkynyl or monocyclic aryl, but is preferably hydrogen, and Z is hydrogen, or

20 Y and Z are linked to form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring, if dihydro-oxathiazine, containing a substituent R¹⁰ as defined above, and X is hydrogen, cyano, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, nitro, -COOR¹¹ or -(CH₂)NR¹²R¹³ wherein R¹¹, R¹² and R¹³ are independently hydrogen or lower alkyl,

and pharmaceutically acceptable salts and esters thereof.

25 The invention also relates to pharmaceutical compositions containing one or more compounds of structural formula (I), and further relates to methods of using the compounds to inhibit estrone sulfatase activity and to treat individuals with disorders that are estrogen-dependent.

DETAILED DESCRIPTION OF THE INVENTION

Definitions and Nomenclature:

30 Before the present compounds, compositions and methods are disclosed and described, it is to be understood that this invention is not limited to specific reagents or reaction conditions, specific pharmaceutical carriers, or to particular administration regimens, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an estrone sulfatase inhibitor" includes mixtures of estrone sulfatase inhibitors, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.

5 In this specification and in the claims which follow, reference will be made to a number of terms which shall be defined to have the following meanings:

The term "alkyl" as used herein refers to a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, octyl, decyl, tetradecyl, hexadecyl, eicosyl, tetracosyl and the like, as well as cycloalkyl groups such as cyclopentyl, cyclohexyl and the like. Preferred alkyl groups herein contain 1 to 12 carbon atoms. The term "lower alkyl" intends an alkyl group of one to six carbon atoms, preferably one to four carbon atoms.

10 The term "alkenyl" as used herein refers to a branched or unbranched hydrocarbon group of 2 to 24 carbon atoms containing at least one double bond, such as ethenyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, t-butenyl, octenyl, decenyl, tetradecenyl, hexadecenyl, eicosenyl, tetracosenyl and the like. Preferred alkenyl groups herein contain 2 to 12 carbon atoms. The term "lower alkenyl" intends an alkenyl group of two to six carbon atoms, preferably two to four carbon atoms. The term "cycloalkenyl" intends a cyclic alkenyl group of three to eight, preferably five or six, carbon atoms.

15 The term "alkynyl" as used herein refers to a branched or unbranched hydrocarbon group of 2 to 24 carbon atoms containing at least one triple bond, such as ethynyl, n-propynyl, isopropynyl, n-butylnyl, isobutylnyl, t-butylnyl, octynyl, decynyl and the like. Preferred alkynyl groups herein contain 2 to 12 carbon atoms. The term "lower alkynyl" intends an alkynyl group of two to six carbon atoms, preferably two to four carbon atoms.

20 The term "alkoxy" as used herein intends an alkyl group bound through a single, terminal ether linkage; that is, an "alkoxy" group may be defined as -OR where R is alkyl as defined above. A "lower alkoxy" group intends an alkoxy group containing one to six, more preferably one to four, carbon atoms.

25 The term "acyl" is used in its conventional sense to refer to a molecular substituent RCO- where R is alkyl as defined above. The term "lower acyl" refers to an acyl group wherein R contains one to six, more preferably one to four, carbon atoms.

30 The term "aryl" as used herein refers to a monocyclic aromatic species of 5 to 7 carbon atoms, and is typically phenyl. Optionally, these groups are substituted with one to four, more preferably one to two, lower alkyl, lower alkoxy or hydroxyl substituents.


The term "inhibitor" as used herein is intended to include both reversible enzyme inhibitors and irreversible enzyme inhibitors, i.e., enzyme inactivators.

"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, the phrase "optional presence of a double bond" to refer to the dotted line in the structure of formula (I) means that either a single bond or a double bond is present. Similarly, the phrase "optionally substituted" as in "optionally substituted dihydro-oxathiazine dioxide ring" means that a non-hydrogen substituent may or may not be present, and the description includes structures wherein a non-hydrogen substituent is present and structures wherein a non-hydrogen substituent is not present.

By the terms "effective amount" or "pharmaceutically effective amount" or "estrone sulfatase inhibiting amount" of an agent as provided herein are meant a nontoxic but sufficient amount of the agent to provide the desired level of enzyme inhibition and corresponding therapeutic effect. As will be pointed out below, the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, and the particular enzyme inhibitor and mode of administration, and the like. Thus, it is not possible to specify an exact "effective amount". However, an appropriate "effective" amount in any individual case may be determined by one of ordinary skill in the art using only routine experimentation.

By "pharmaceutically acceptable carrier" is meant a material which is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the selected estrone sulfatase inhibitor without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. Similarly, a "pharmaceutically acceptable" salt or a "pharmaceutically acceptable" ester of a novel compound as provided herein is a salt or ester which is not biologically or otherwise undesirable.

In describing the location of groups and substituents, the following numbering systems will be employed. This system is intended to conform the numbering of the cyclopentanophenanthrene nucleus to the convention used by the IUPAC or Chemical Abstracts Service. The term "steroid" as used herein is intended to mean compounds having the aforementioned cyclopentanophenanthrene nucleus.



In these structures, the use of bold and dashed lines to denote particular conformation of groups again follows the IUPAC steroid-naming convention. The symbols " α " and " β " indicate the specific stereochemical configuration of a substituent at an asymmetric carbon atom in a chemical structure as drawn. Thus " α ," denoted by a broken line, indicates that the group in question is below the general plane of the molecule as drawn, and " β ," denoted by a bold line, indicates that the group at the position in question is above the general plane of the molecule as drawn.

In addition, the five- and six-membered rings of the steroid molecule are often designated A, B, C and D as shown.



The Novel Compounds:

The novel compounds provided herein are those defined by structural formula (I), wherein n , q_1 , q_2 , R^1 , R^2 , R^3 , R^4 , R^5 , X , Y and Z are as defined above.

Preferred compounds within this group are wherein one of R^1 and R^2 is hydrogen, and the other is selected from the group consisting of hydroxyl, lower alkyl, lower alkoxy, lower acyl and ethynyl, or wherein R^1 and R^2 together form $=O$ or $=C(R^8R^9)$ in which R^8 and R^9 are independently selected from the group consisting of hydrogen, $-CHO$, methyl, ethyl, n -propyl and cyano, or together form a $=CH_2$ substituent.

Also, as explained above, X and Y may be linked to form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring, if dihydro-oxathiazine, bearing a substituent R^{10} on the carbon atom of the ring adjacent to the A ring, wherein R^{10} is hydrogen, lower alkyl, lower alkynyl or monocyclic aryl. Examples of specific R^{10} substituents, in addition to hydrogen, include methyl, ethynyl and phenyl. In this embodiment, when X and Y are linked, Z is hydrogen. Such compounds, wherein X


and Y are linked to form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring which may or may not be substituted have the structural formulae (II) or (III) respectively:




Alternatively, Y and Z may be linked to form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring, and, as above, if the ring is "dihydro," again, it contains a substituent R^{10} present on the carbon atom adjacent to the A ring, wherein R^{10} is hydrogen, lower alkyl, lower alkynyl or monocyclic aryl. Examples of specific R^{10} groups are as set out above with respect to a heterocyclic ring formed from X and Y. In this case, when Y and Z are linked, X may be hydrogen, cyano, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, nitro, $-COOR^{11}$ or $-(CH_2)NR^{12}R^{13}$ wherein R^{11} , R^{12} and R^{13} are independently hydrogen or lower alkyl.

These latter compounds, wherein Y and Z are linked to form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring which may or may not be substituted have the structural formulae (IV) or (V) respectively:


(IV)






(V)







Examples of specific compounds of formula (I) include, but are not limited to, the following:











30




30





and



The novel compounds also include pharmaceutically acceptable salts and esters of compounds of Formula (I), as explained in the next section.

Utility and Administration:

5 The compounds defined by structural formula (I) are useful as estrone sulfatase inhibitors and are therefore useful for the treatment of estrogen-dependent disorders, i.e., conditions or diseases that are estrogen-induced or estrogen stimulated. Since the present compounds can lower circulating estrogen levels, they can effectively prevent biologically active estrogens from reaching endocrine tumors. In addition, since the present compounds can reduce estrogen biosynthesis in tumors capable
10 of endogenous estrogen synthesis, the compounds are capable of inducing remission in breast cancer, including metastatic tumors. Furthermore, the present compounds have utility in the treatment of ovarian, uterine and pancreatic tumors as well as disease conditions such as galactorrhea, McCune-Albright syndrome, benign breast disease, and endometriosis.

 The compounds may be conveniently formulated into pharmaceutical compositions composed
15 of one or more of the compounds in association with a pharmaceutically acceptable carrier. See *Remington's Pharmaceutical Sciences* (Mack Publ. Co., Easton PA), which discloses typical carriers and conventional methods of preparing pharmaceutical compositions which may be used to prepare formulations using the novel enzyme inhibitors of the invention. The compounds may also be administered in the form of pharmaceutically acceptable salts, or in the form of pharmaceutically
20 acceptable esters. Salts of the compounds may be prepared using standard procedures known to those skilled in the art of synthetic organic chemistry and described, for example, by J. March, *Advanced Organic Chemistry: Reactions, Mechanisms and Structure*, 4th Ed. (New York: Wiley-Interscience, 1992). Preparation of esters involves functionalization of hydroxyl and/or carboxyl groups which may be present at various positions on the steroid molecule. These esters may derive from organic acid or
25 inorganic acid functionalities at those positions, but are typically acyl-substituted derivatives of free alcohol groups, i.e., moieties which are derived from carboxylic acids of the formula RCOOH where R is alkyl, and preferably is lower alkyl.

 The compounds may be administered orally, parenterally (e.g., intravenously), topically, transdermally, by intramuscular injection, or by intraperitoneal injection, or the like, although oral
30 administration is preferred for those compounds which have oral activity. The amount of active compound administered will, of course, be dependent on the subject being treated, the subject's weight, the manner of administration and the judgment of the prescribing physician. Generally, however, dosage will be in the range of approximately 0.01 mg/kg/day to 10.0 mg/kg/day, more preferably in the range of about 1.0 mg/kg/day to 5.0 mg/kg/day.

Depending on the intended mode of administration, the pharmaceutical compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage form suitable for single administration of a precise dosage. The compositions will include, as noted above, an effective amount of the selected drug in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc.

For solid compositions, conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc., an active compound as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington's Pharmaceutical Sciences*, referenced above.

For oral administration, fine powders or granules may contain diluting, dispersing, and/or surface active agents, and may be presented in water or in a syrup, in capsules or sachets in the dry state, or in a nonaqueous solution or suspension wherein suspending agents may be included, in tablets wherein binders and lubricants may be included, or in a suspension in water or a syrup. Where desirable or necessary, flavoring, preserving, suspending, thickening, or emulsifying agents may be included. Tablets and granules are preferred oral administration forms, and these may be coated.

Parenteral administration, if used, is generally characterized by injection. Injectable formulations can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system, such that a constant level of dosage is maintained. See, e.g., U.S. Patent No. 3,710,795.

Process for Preparation:

The compounds of the invention may be prepared in high yield using relatively simple, straightforward methods as exemplified in the experimental section herein. Synthesis of representative compounds are detailed in Examples.

Experimental:

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of synthetic organic chemistry, biological testing, and the like, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Fieser et al., *Steroids* (New York: Reinhold, 1959), Djerassi, *Steroid Reactions: An Outline for Organic Chemists* (San Francisco: Holden-Day, 1963), and Fried et al., *Organic Reactions in Steroid Chemistry*, vols. 1 and 2 (New York: Reinhold, 1972), for detailed information concerning steroid-related synthetic procedures. Reference may be had to MacIndoe et al., *Endocrinology* 123(3):1281-1287 (1988), Duncan et al., *Cancer Res.* 53:298-303 (1993), and Yue et al., *J. Steroid Biochem.* 44:671-673 (1993), for a description of the biological testing procedures useful to evaluate compounds such as those described and claimed herein.

It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, that the description above as well as the examples which follow are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

In the following examples, efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental error and deviation should be accounted for. Unless indicated otherwise, temperature is in degrees C and pressure is at or near atmospheric.

All solvents were purchased as HPLC grade, and all reactions were routinely conducted under an inert atmosphere of argon unless otherwise indicated. All reagents were obtained commercially unless otherwise indicated. Estrone and estradiol were purchased from Berlichem U.S.; ethynyl estradiol was purchased from Akzo Nobel. NMR analyses were conducted on either a Varian Gemini 300 and were referenced to chloroform at δ 7.27. FTIR spectra were recorded on a Perkin-Elmer 1610.

Example 1

Preparation of 17 β -Acetoxystro-1,3,5(10)-
trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (4)

5


10

15

20

25

30

Scheme 1

(a) Synthesis of 3,17 β -dihydroxystro-1,3,5(10)-trien-2-carboxaldehyde (2a) and 3,17 β -dihydroxystro-1,3,5(10)-trien-4-carboxaldehyde (2b):

SUBSTITUTE SHEET (RULE 26)

To a mixture of estradiol (1, 13.6 g, 50 mmol) and hexamethylene-tetramine (21.0 g, 150 mmol) was added trifluoroacetic acid (100 mL) at room temperature. The reaction mixture was stirred for 6 h at 100°C, poured into H₂O (300 mL), and extracted with Et₂O. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (MgSO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was dissolved in THF (50 mL) and MeOH (50 mL), potassium carbonate (6.9 g, 50 mmol) was added, and the mixture stirred for 1 h at room temperature. The reaction mixture was then diluted with EtOAc, acidified with 1 N HCl, and extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (MgSO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:THF (5:1-3:1, v/v) to afford 1.91 g of **2a** (13% yield), m.p. 219-221°C. and 0.552 g of **2b** (4% yield), m.p. 146-147°C.

2a: ¹H NMR: δ 10.77 (s, 1H, -OH), 9.81 (s, 1H, -CHO), 7.42 (s, 1H, aromatic), 6.70 (s, 1H, aromatic), 3.74 (t, 1H, 17α-H), 0.79 (s, 3H, 18-CH₃); MS (EI): *m/z* 300 (M⁺).

2b: ¹H NMR: δ 12.03 (s, 1H, -OH), 10.42 (s, 1H, -CHO), 7.53 (d, 1H, aromatic), 6.83 (d, 1H, aromatic), 3.79 (t, 1H, 17α-H), 0.84 (s, 3H, 18-CH₃); MS (EI): *m/z* 300 (M⁺).

(b) Alternative preparation of **2a**: To a suspension of magnesium (2.07 g, 85 mmol) in THF (20 mL) was added bromoethane (8.9 mL, 119 mmol) dissolved in THF (15 mL) at room temperature. Estradiol (1, 4.63 g, 17 mmol) dissolved in THF (40 mL) was added to the reaction mixture, and stirring continued for 30 min. The solvent was removed at reduced pressure, and to the residue were added benzene (200 mL), hexamethylphosphoric triamide (7.4 mL, 42.5 mmol) and paraformaldehyde (7.00 g). Stirring was continued for 20 h at 80°C. After the reaction mixture was cooled to room temperature, 5 N HCl (150 mL) was added and the mixture extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was dissolved in MeOH (200 mL), 20% aqueous sodium hydroxide (25 mL) added, and the mixture stirred for 30 min at room temperature. The reaction mixture was acidified with 5 N HCl at 0°C, the solvent evaporated at reduced pressure, and the residue extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:THF (5:1-2:1, v/v) to afford 4.81 g of **2a** (94% yield).

¹H NMR: δ 10.77 (s, 1H, -OH), 9.81 (s, 1H, -CHO), 7.42 (s, 1H, aromatic), 6.70 (s, 1H, aromatic), 3.74 (t, 1H, 17α-H), 0.79 (s, 3H, 18-CH₃); MS (EI): *m/z* 300 (M⁺).

(c) Synthesis of 3,17β-dihydroxyestra-1,3,5(10)-triene-2-carboxaldehyde 17-acetate (**3**):

SUBSTITUTE SHEET (RULE 26)


To a suspension of 3,17 β -dihydroxyestra-1,3,5(10)-triene-2-carboxaldehyde (**2a**, 0.150 g, 0.50 mmol) in acetic acid (3.0 mL) was added sodium acetate (0.600 g, 7.5 mmol) at room temperature. The reaction mixture was stirred for 24 h under reflux. After the reaction mixture was cooled to room temperature, it was diluted with EtOAc, washed with H₂O, then with saturated aqueous NaCl, and dried (MgSO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (5:1, v/v) to afford 0.144 g of **3** (84% yield), m.p. 184-185°C.

¹H NMR: δ 10.82 (s, 1H, -OH), 9.86 (s, 1H, -CHO), 7.47 (s, 1H, aromatic), 6.75 (s, 1H, aromatic), 4.75 (t, 1H, 17 α -H), 2.11 (s, 3H, -OCOCH₃), 0.89 (s, 3H, 18-CH₃); MS (EI): *m/z* 342 (M⁺).

(d) Synthesis of 17 β -acetoxystro-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**4**):

To a solution of chlorosulfonyl isocyanate (0.17 mL, 1.9 mmol) in CH₂Cl₂ (1.5 mL) was added formic acid (0.38 mL of a CH₂Cl₂ solution, 5.0 M, 1.9 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 h. To a solution of 3,17 β -dihydroxyestra-1,3,5(10)-triene-2-carboxaldehyde 17-acetate (**3**, 0.133 g, 0.39 mmol) in DMF (5.0 mL) was added sodium hydride (0.031 g of a mineral oil dispersion, 60%, 0.78 mmol) at 0 °C. The reaction mixture was stirred for 1 h, the pre-prepared reagent was added, and stirring continued for 5 h at room temperature. The reaction mixture was quenched with saturated aqueous NH₄Cl at 0 °C, then extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (MgSO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:acetone (4:1-3:1, v/v) to afford 0.084 g of the starting material **3** (63% yield) and 0.029 g of **4** (19% yield), m.p. 202-203°C.

¹H NMR: δ 8.62 (s, 1H, -CH=N-), 7.57 (s, 1H, aromatic), 7.03 (s, 1H, aromatic), 4.75 (t, 1H, 17 α -H), 2.10 (s, 3H, -OCOCH₃), 0.88 (s, 3H, 18-CH₃); MS (EI): *m/z* 403 (M⁺). HRMS calcd. for C₂₁H₂₆N₁O₅S₁, 404.1532; found, 404.1525.

Example 2Preparation of Estra-1,3,5(10)-trien-17-ono-
[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (6)Scheme 2

(a): Synthesis of 3-hydroxyestra-1,3,5(10)-trien-17-one-2-carboxaldehyde (5):

To a solution of 3,17β-dihydroxyestra-1,3,5(10)-triene-2-carboxaldehyde (2a, 0.300 g, 1.0 mmol) in acetone (20 mL) was added Jones reagent (0.5 mL) at 0°C. The reaction mixture was stirred for 5 min, then quenched with 2-propanol, and extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (MgSO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:THF (4:1-3:1, v/v) to approximately 0.185 g of 5 (62% yield), m.p. 154-157°C.

¹H NMR: δ 10.83 (s, 1H, -OH), 9.86 (s, 1H, -CHO), 7.47 (s, 1H, aromatic), 6.77 (s, 1H, aromatic), 0.97 (s, 3H, 18-CH₃).

(d) Synthesis of estra-1,3,5(10)-trien-17-ono-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (6):


To a solution of chlorosulfonyl isocyanate (4.3 mL, 50 mmol) in CH₂Cl₂ (25 mL) was added formic acid (10 mL of a CH₂Cl₂ solution, 5.0 M, 50 mmol) at 0°C. The reaction mixture was warmed to room temperature and stirred for 1 h. To a solution of 3-hydroxyestra-1,3,5(10)-trien-17-one-2-carboxaldehyde (5, 2.98 g, 10 mmol) in DMF (120 mL) was added sodium hydride (2.00 g of a mineral oil dispersion, 60%, 50 mmol) at 0°C. The reaction mixture was stirred for 1 h, the

pre-prepared reagent was added, and stirring continued for 4 h. The reaction mixture was quenched with saturated aqueous NH_4Cl at 0°C , then extracted with EtOAc. The combined organic layers were washed with H_2O , then with saturated aqueous NaCl , and dried (Na_2SO_4). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using CHCl_3 :EtOAc (20:1 - 10:1, v/v) to afford 0.696 g of the starting material **5** (23% yield) and 1.88 g of **6** (52% yield), m.p. $> 250^\circ\text{C}$.

^1H NMR: δ 8.63 (s, 1H, $-\text{CH}=\text{N}-$), 7.59 (s, 1H, aromatic), 7.06 (s, 1H, aromatic), 0.98 (s, 3H, $18-\text{CH}_3$); MS (EI): m/z 359 (M^+). HRMS calcd. for $\text{C}_{19}\text{H}_{20}\text{N}_1\text{O}_4\text{S}_1$, 358.1113; found, 358.1140.

Example 3

Preparation of 17 β -Hydroxyestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**10**)



Scheme 3

(a) Synthesis of 3,17 β -dihydroxyestra-1,3,5(10)-triene-2-carboxaldehyde 3-acetate (7):

To a solution of 3,17 β -dihydroxyestra-1,3,5(10)-triene-2-carboxaldehyde (2a, 0.300 g, 1.0 mmol) in THF (10 mL) and CH₂Cl₂ (6.0 mL) were added triethylamine (0.34 mL, 2.5 mmol) and acetic anhydride (0.14 mL, 1.5 mmol) at room temperature. The reaction mixture was stirred for 18 h, H₂O added, and the mixture extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (MgSO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (3:2, v/v) to afford 0.336 g of 7 (98% yield), m.p. 73-75 °C.

¹H NMR: δ 7.83 (s, 1H, aromatic), 6.91 (s, 1H, aromatic), 3.78 (t, 1H, 17 α -H), 2.42 (s, 3H, -OCOCH₃), 0.83 (s, 3H, 18-CH₃).

(b) Synthesis of 17 β -tert-butyldimethyl-silyloxy-3-hydroxyestra-1,3,5(10)-triene-2-carboxaldehyde 3-acetate (8):

To a solution of 3,17 β -dihydroxyestra-1,3,5(10)-triene-2-carboxaldehyde 3-acetate (7, 0.330 g, 0.97 mmol) in DMF (2.0 mL) were added imidazole (0.131 g, 1.9 mmol) and tert-butyldimethylchlorosilane (0.218 g, 1.5 mmol) at room temperature. The reaction mixture was stirred for 2 h, diluted with EtOAc, washed with H₂O, then with saturated aqueous NaCl, and dried (MgSO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (10:1-3:1, v/v) to afford 0.195 g of 8 (44% yield).

¹H NMR: δ 9.98 (s, 1H, -CHO), 7.74 (s, 1H, aromatic), 6.83 (s, 1H, aromatic), 3.62 (t, 1H, 17 α -H), 2.34 (s, 3H, -OCOCH₃), 0.87 (s, 9H, -C(CH₃)₃), 0.72 (s, 3H, 18-CH₃), 0.01 and 0.00 (s, each 3H, -Si(CH₃)₂).

(c) Synthesis of 17 β -tert-butyldimethylsilyloxy-3-hydroxyestra-1,3,5(10)-triene-2-carboxaldehyde (9):

To a solution of 17 β -tert-butyldimethylsilyloxy-3-hydroxyestra-1,3,5(10)-triene-2-carboxaldehyde 3-acetate (8, 0.190 g, 0.42 mmol) in MeOH (3.0 mL) was added potassium carbonate (0.058 g, 0.42 mmol) at 0 °C. The reaction mixture was stirred for 1 h, diluted with EtOAc, washed with H₂O, then with saturated aqueous NaCl, and dried (MgSO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (10:1, v/v) to afford 0.135 g of 9 (81% yield).

¹H NMR: δ 10.74 (s, 1H, -OH), 9.79 (s, 1H, -CHO), 7.39 (s, 1H, aromatic), 6.66 (s, 1H, aromatic), 3.62 (t, 1H, 17 α -H), 0.87 (s, 9H, -C(CH₃)₃), 0.72 (s, 3H, 18-CH₃), 0.01 and 0.00 (s, each 3H, -Si(CH₃)₂).


(d) Synthesis of 17 β -hydroxyestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (10):

To a solution of chlorosulfonyl isocyanate (0.13 mL, 1.5 mmol) in CH₂Cl₂ (1.0 mL) was added formic acid (0.31 mL of a CH₂Cl₂ solution, 5.0 M, 1.6 mmol) at 0°C. The reaction mixture was warmed to room temperature and stirred for 1 h. To a solution of 17 β -tert-butyl-dimethylsilyloxy-3-hydroxyestra-1,3,5(10)-triene-2-carboxaldehyde (9, 0.129 g, 0.31 mmol) in DMF (3.0 mL) was added sodium hydride (0.044 g of a mineral oil dispersion, 60%, 1.1 mmol) at 0°C. The reaction mixture was stirred for 1 h, the pre-prepared reagent was added, and stirring continued for 4 h at room temperature. The reaction mixture was quenched with saturated aqueous NH₄Cl at 0 °C and extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (MgSO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:acetone (2:1-1:1, v/v) to afford 0.017 g of 2a (18% yield) and 0.030 g of 10 (27% yield), m.p. 170-172°C.

¹H NMR: δ 8.62 (s, 1H, -CH=N-), 7.58 (s, 1H, aromatic), 7.03 (s, 1H, aromatic), 3.78 (t, 1H, 17 α -H), 0.84 (s, 3H, 18-CH₃); MS (EI): m/z 361 (M⁺). HRMS calcd. for C₁₉H₂₄N₁O₄S₁, 362.1426; found 362.1448.

Example 4

Preparation of 17 β -Hydroxyestra-1,3,5(10)-trieno-[3,2,e]-3',4'-dihydro-1',2',3'-oxathiazine-2',2'-dioxide (11)



Scheme 4


To a solution of 17 β -hydroxyestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-

2',2'-dioxide (**10**, 0.024 g, 0.067 mmol) in MeOH (2.0 mL) was added sodium borohydride (0.005 g, 0.13 mmol) at 0°C. The reaction mixture was stirred for 30 min, quenched with saturated aqueous NH₄Cl at 0°C, and extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (MgSO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using CHCl₃:MeOH (20:1, v/v) to afford 0.019 g of **11** (80% yield), m.p. 231-232°C.

¹H NMR (CDCl₃-CD₃OD): δ 6.94 (s, 1H, aromatic), 6.64 (s, 1H, aromatic), 4.49 (s, 2H, -CH₂N-), 3.64 (t, 1H, 17α-H), 0.74 (s, 3H, 18-CH₃); MS (EI): *m/z* 363 (M⁺). HRMS calcd. for C₁₉H₂₅N₁O₄S₁, 362.1426; found, 362.1449.

Example 5

Preparation of Estra-1,3,5(10)-trien-17-ono-[3,4,e]- 1',2',3'-oxathiazine-2',2'-dioxide (**13**)



Scheme 5

(a) Synthesis of 3-hydroxyestra-1,3,5(10)-trien-17-one-4-carboxaldehyde (**12**):

To a solution of 3,17β-dihydroxyestra-1,3,5(10)-triene-4-carboxaldehyde (**2b**, 0.300 g, 1.0 mmol) in acetone (10 mL) was added Jones reagent (0.50 mL) at 0°C. The reaction mixture was stirred for 10 min, quenched with 2-propanol, and extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column

chromatography (silica gel) using n-hexane:THF (4:1-2:1, v/v) to afford 0.276 g of **12** (93% yield), m.p. 234-237°C.

¹H NMR: δ 12.04 (s, 1H, -OH), 10.44 (s, 1H, -CHO), 7.53 (d, 1H, aromatic), 6.85 (d, 1H, aromatic), 0.97 (s, 3H, 18-CH₃).


(b) Synthesis of estra-1,3,5(10)-trien-17-ono-[3,4,e]-1',2',3'-oxathiazine-2',2'-dioxide (13):

To a solution of chlorosulfonyl isocyanate (0.30 mL, 3.5 mmol) in CH₂Cl₂ (2.0 mL) was added formic acid (0.70 mL of a CH₂Cl₂ solution, 5.0 M, 3.5 mmol) at 0°C. The reaction mixture was warmed to room temperature and stirred for 1 h. To a solution of 3-hydroxyestra-1,3,5(10)-trien-17-one-4-carboxaldehyde (**12**, 0.207 g, 0.69 mmol) in DMF (10 mL) was added sodium hydride (0.140 g of a mineral oil dispersion, 60%, 3.5 mmol) at 0°C. The reaction mixture was stirred for 1 h, the pre-prepared reagent was added, and stirring continued for 3 h at room temperature. The reaction mixture was quenched with saturated aqueous NH₄Cl at 0°C, and extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:THF (3:1-2:1, v/v) to afford 0.069 g of **12** (34% yield) and 0.090 g of **13** (37% yield), m.p. 94-96°C.

¹H NMR: δ 9.00 (s, 1H, -CH=N-), 7.72 (d, 1H, aromatic), 7.13 (d, 1H, aromatic), 0.97 (s, 3H, 18-CH₃); MS (EI): *m/z* 359 (M⁺). HRMS calcd. for C₁₉H₂₀N₁O₄S₁, 358.1113; found, 358.1128.

Example 6

Preparation of 17 β -Hydroxyestra-1,3,5(10)-trieno-[3,4,e]-3',4'-dihydro-1',2',3'-oxathiazine-2',2'-dioxide (14)



Scheme 6


To a solution of estra-1,3,5(10)-trien-17-ono-[3,4,e]-1',2',3'-oxathiazine-2',2'-dioxide (13, 0.036 g, 0.10 mmol) in MeOH (2.0 mL) was added sodium borohydride (0.006 g, 0.16 mmol) at 0°C. The reaction mixture was stirred for 30 min, and quenched with saturated aqueous NH₄Cl at 0°C, and

extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using CHCl₃:acetone (5:1-3:1, v/v) to afford 0.024 g of **14** (67% yield), m.p. > 250°C.

¹H NMR (CDCl₃-CD₃OD): δ 7.26 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 4.44 (AB type, 2H, -CH₂N-), 3.69 (t, 1H, 17α-H), 0.76 (s, 3H, 18-CH₃); MS (EI): *m/z* 363 (M⁺). HRMS calcd. for C₁₉H₂₅N₄O₄S₁, 363.1504; found, 363.1529.

Example 7

Preparation of 19-Norpregna-1,3,5(10)-trieno-[3,2,e]- 1',2',3'-oxathiazine-2',2'-dioxide (**17**)



Scheme 7

(a) Synthesis of 3-hydroxy-19-norpregna-1,3,5(10)-triene-2-carboxaldehyde (**16**):

To a suspension of magnesium (0.243 g, 10 mmol) in THF (2.0 mL) was added bromoethane (0.90 mL, 12 mmol), dissolved in THF (2.0 mL) at room temperature. 19-Norpregna-1,3,5(10)-trien-3-ol (**15**, 0.569 g, 2.0 mmol; synthesized by the method of Peters et al., *J. Med. Chem.* **32**(7):1642 (1989)) dissolved in THF (5.0 mL) was added to the reaction mixture, and stirring continued for 30 min. The solvent was removed at reduced pressure, and to the residue were added benzene (23 mL), hexamethylphosphoric triamide (0.9 mL, 5.0 mmol) and paraformaldehyde (0.420 g). Stirring was continued for 3 h at 80°C. After the reaction mixture was cooled to room temperature, 5 N HCl (10 mL) was added and the mixture extracted with EtOAc. The combined organic layers were washed

SUBSTITUTE SHEET (RULE 26)

with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:CHCl₃ (2:1-1:1, v/v) to afford 0.493 g of 16 (80% yield), m.p. 126-127°C.


¹H NMR: δ 10.77 (s, 1H, -OH), 9.81 (s, 1H, -CHO), 7.42 (s, 1H, aromatic), 6.69 (s, 1H, aromatic), 0.91 (t, 3H, 21-CH₃), 0.62 (s, 3H, 18-CH₃); MS (EI): *m/z* 312(M⁺).

(b) Synthesis of 19-norpregna-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (17):

To a solution of chlorosulfonyl isocyanate (0.26 mL, 3.0 mmol) in CH₂Cl₂ (1.0 mL) was added formic acid (0.60 mL of a CH₂Cl₂ solution, 5.0 M, 3.0 mmol) at 0°C. The reaction mixture was warmed to room temperature and stirred for 1 h. To a solution of 3-hydroxy-19-norpregna-1,3,5(10)-triene-2-carboxaldehyde (16, 0.187 g, 0.6 mmol) in DMF (3.0 mL) and THF (2.0 mL) was added sodium hydride (0.120 g of a mineral oil dispersion, 60%, 3.0 mmol) at 0°C. The reaction mixture was stirred for 1 h, the pre-prepared reagent was added, and stirring continued for 1 h at 0°C and additional 16 h at room temperature. The reaction mixture was quenched with saturated aqueous NH₄Cl at 0°C and extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:CHCl₃ (1:1, v/v) hexane:CHCl₃:EtOAc (5:5:1, v/v) to afford 0.089 g of 16 (47% yield) and 0.069 g of 17 (31% yield), m.p. 173-174°C.

¹H NMR: δ 8.58 (s, 1H, -CH=N-), 7.53 (s, 1H, aromatic), 6.98 (s, 1H, aromatic), 0.91 (t, 3H, 21-CH₃), 0.62 (s, 3H, 18-CH₃); MS (EI): *m/z* 373(M⁺). HRMS calcd. for C₂₁H₂₈N₁O₃S₁, 374.1790; found, 374.1806.

The following scheme illustrates the synthetic steps carried out in Examples 8 through 14 to make the enzyme inhibitors (30), (31), (32), (33), (34), (35) and (36):



Scheme 8

Example 8

Preparation of 17-Methyleneestra-1,3,5(10)-trien-
[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (30)

(a) Synthesis of 17-methyleneestra-1,3,5(10)-trien-3-ol (19):

To a suspension of methyl triphenylphosphonium bromide (8.93 g, 25.0 mmol) in THF (120 mL) was added potassium *tert*-butoxide (2.69 g, 24 mmol) and stirred for 30 min at room temperature. The reaction mixture was added estrone (18, 2.70 g, 10 mmol), stirred for 19 h at room temperature. The reaction mixture was quenched with saturated aqueous NH_4Cl at 0°C and extracted with EtOAc. The combined organic layers were washed with H_2O , then with saturated aqueous NaCl, and dried (Na_2SO_4). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue

was purified by column chromatography (silica gel) using n-hexane:EtOAc (5:1-3:1, v/v) to afford 2.24 g of **19** (84% yield), m.p. 135-136°C.

¹H NMR: δ 7.17 (d, 1H, aromatic), 6.68-6.52 (m, 2H, aromatic), 4.73-4.55 (m, 3H, -OH, =CH₂), 0.82 (s, 3H, 18-CH₃).

5 (b) Preparation of [17(20)Z]-19-norpregna-1,3,5(10),17(20)-tetraen-3-ol (**20**):

To a suspension of ethyl triphenylphosphonium bromide (4.64 g, 12.5 mmol) in THF (40 mL) was added potassium tert-butoxide (1.35 g, 12 mmol) and stirred for 30 min at room temperature. The reaction mixture was added estrone (**18**, 1.35 g, 5.0 mmol), stirred for 24 h at room temperature. The reaction mixture was quenched with saturated aqueous NH₄Cl at 0°C and extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (5:1-2:1, v/v) to afford 1.03 g of **20** (72% yield), m.p. 138-139°C.

15 ¹H NMR: δ 7.16 (d, 1H, aromatic), 6.68-6.50 (m, 2H, aromatic), 5.22-5.08 (m, 1H, =CH-CH₃), 4.48 (s, 1H, -OH), 1.72-1.65 (m, 3H, =CH-CH₃), 0.91 (s, 3H, 18-CH₃).

(c) Preparation of [17(20)Z]-propylideneestra-1,3,5(10)-trien-3-ol (**21**):

To sodium hydride (1.20 g of a mineral oil dispersion, 60%, 30.0 mmol) was added DMSO (100 mL) and the mixture stirred for 1 h at 75°C. To the reaction mixture was added propyl triphenylphosphonium bromide (12.3 g, 32.0 mmol), and stirring continued for 30 min at room temperature. To the reaction mixture was added estrone (**18**, 2.70 g, 10 mmol), stirred for 4 days at 80°C. The reaction mixture was quenched with saturated aqueous NH₄Cl at 0°C and extracted with Et₂O. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (10:1-1:1, v/v) to afford 1.30 g of **21** (44% yield) and 1.05 g of **18** (39% yield), m.p. 149-151°C.

25 ¹H NMR: δ 7.15 (d, 1H, aromatic), 6.68-6.50 (m, 2H, aromatic), 5.12-5.00 (m, 1H, =CH-CH₂-), 4.57 (s, 1H, -OH), 0.96 (t, 3H, 23-CH₃), 0.90 (s, 3H, 18-CH₃).

(d) Preparation of [17(20)Z]-19,21-dinorchola-1,3,5(10),17(20)-tetraen-3-ol (**22**):

30 To a suspension of butyl triphenylphosphonium bromide (12.8 g, 32.0 mmol) in THF (100 mL) was added potassium *tert*-butoxide (3.37 g, 30 mmol) and stirred for 30 min at room temperature. To the reaction mixture was added estrone (**18**, 2.70 g, 10 mmol), and stirring continued for 5 days at 80°C. The reaction mixture was quenched with saturated aqueous NH₄Cl at 0°C and extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The

residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (10:1-2:1, v/v) to afford 2.45 g of **22** (79% yield), m.p. 85-86°C.

¹H NMR: δ 7.15 (d, 1H, aromatic), 6.70-6.52 (m, 2H, aromatic), 5.13-5.00 (m, 1H, =CH-CH₂-), 4.49 (s, 1H, -OH), 0.91 (t, 3H, 24-CH₃), 0.90 (s, 3H, 18-CH₃).

5 (e) Preparation of 3-hydroxy-17-methylene-estra-1,3,5(10)-triene-2-carboxaldehyde (**23**):

To a suspension of magnesium (0.365 g, 15 mmol) in THF (3.0 mL) was added bromoethane (1.5 mL, 20 mmol) dissolved in THF (3.0 mL) at room temperature. 17-Methyleneestra-1,3,5(10)-trien-3-ol (**19**, 0.805 g, 3.0 mmol) dissolved in THF (7.5 mL) was added to the reaction mixture, and stirring continued for 30 min. The solvent was removed at reduced pressure, and to the residue were added benzene (35 mL), hexamethylphosphoric triamide (1.4 mL, 7.5 mmol) and paraformaldehyde (0.630 g). Stirring was continued for 6 h at 80°C. After the reaction mixture was cooled to room temperature, 5 N HCl (15 mL) was added and the mixture extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:AcOEt (10:1-3:1, v/v) to afford 0.695 g of **23** (78% yield), m.p. 128-130°C.

¹H NMR: δ 10.78 (s, 1H, -OH), 9.82 (s, 1H, -CHO), 7.44 (s, 1H, aromatic), 6.70 (s, 1H, aromatic), 4.85-4.58 (m, 2H, =CH₂), 0.84 (s, 3H, 18-CH₃).

20 (f) Preparation of 17-methyleneestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**30**):

To a solution of chlorosulfonyl isocyanate (0.43 mL, 5.0 mmol) in CH₂Cl₂ (2.0 mL) was added formic acid (1.0 mL of a CH₂Cl₂ solution, 5.0 M, 5.0 mmol) at 0°C. The reaction mixture was warmed to room temperature and stirred for 1 h. To a solution of 3-hydroxy-17-methyleneestra-1,3,5(10)-triene-2-carboxaldehyde (**23**, 0.267 g, 0.9 mmol) in DMF (5.0 mL) was added sodium hydride (0.200 g of a mineral oil dispersion, 60%, 5.0 mmol) at 0°C. The reaction mixture was stirred for 1 h, the pre-prepared reagent was added, and stirring continued for 2 h at 0°C. The reaction mixture was quenched with saturated aqueous NH₄Cl at 0°C and extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (10:1, v/v)-CHCl₃:EtOAc (20:1, v/v) to afford 0.254 g of **30** (79% yield), m.p. 176-179°C.

¹H NMR: δ 8.59 (s, 1H, -CH=N-), 7.55 (s, 1H, aromatic), 6.99 (s, 1H, aromatic), 4.78-4.63 (m, 2H, =CH₂), 0.84 (s, 3H, 18-CH₃); MS (DCI): m/z 375 (M⁺+NH₄), 358 (M⁺+H). HRMS calcd. for C₂₀H₂₄N₁O₄S₁, 358.1477; found, 358.1486.

Example 9Preparation of [17(20)Z]-Norpregna-1,3,5(10),17(20)-tetraeno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (31)

(a) 3-Hydroxy-[17(20)Z]-19-norpregna-1,3,5(10),17(20)-tetraene-2-carboxaldehyde (**24**):

Using the procedure of Example 8, part (e), there was obtained from [17(20)Z]-19-norpregna-1,3,5(10),17(20)-tetraen-3-ol (**20**, 0.480 g, 1.7 mmol) after chromatography (n-hexane:AcOEt, 30:1-10:1, v/v), 0.495 g of **24** (94% yield), m.p. 107-109°C.

¹H NMR: δ 10.78 (s, 1H, -OH), 9.82 (s, 1H, -CHO), 7.42 (s, 1H, aromatic), 6.70 (s, 1H, aromatic), 5.34-5.06 (m, 1H, =CH-CH₃), 1.78-1.66 (m, 3H, =CH-CH₃), 0.92 (s, 3H, 18-CH₃); MS (EI): m/z 310 (M⁺).

(b) Preparation of [17(20)Z]-norpregna-1,3,5(10),17(20)-tetraeno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**31**):

Using the procedure of Example 8, part (f), there was obtained from 3-hydroxy-[17(20)Z]-norpregna-1,3,5(10),17(20)-tetraene-2-carboxaldehyde (**24**, 0.310 g, 1.0 mmol) after chromatography (n-hexane:CHCl₃:EtOAc, 15:15:1, v/v) 0.276 g of **31** (74% yield), m.p. 185-186°C.

¹H NMR: δ 8.59 (s, 1H, -CH=N-), 7.53 (s, 1H, aromatic), 6.99 (s, 1H, aromatic), 5.25-5.05 (m, 1H, =CH-CH₃), 1.75-1.65 (m, 3H, =CH-CH₃), 0.92 (s, 3H, 18-CH₃); MS (DCI): m/z 389 (M⁺+NH₄), 372 (M⁺+H). HRMS calcd. for C₂₁H₂₆N₁O₃S₁, 372.1633; found, 372.1656.

Example 10Preparation of [17(20)Z]-Norpregna-1,3,5(10),17(20)-tetraeno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (32)

(a) Preparation of 3-hydroxy-[17(20)Z]-propylideneestra-1,3,5(10)-triene-2-carboxaldehyde (**25**):

Using the procedure of Example 8, part (e), there was obtained from [17(20)Z]-propylideneestra-1,3,5(10)-triene-3-ol (**21**, 1.03 g, 3.5 mmol) after chromatography (n-hexane:AcOEt, 30:1-10:1, v/v), 0.983 g of **25** (87% yield).

¹H NMR: δ 10.77 (s, 1H, -OH), 9.82 (s, 1H, -CHO), 7.42 (s, 1H, aromatic), 6.70 (s, 1H, aromatic), 5.13-4.98 (m, 1H, =CH-CH₂-), 0.97 (t, 3H, 23-CH₃), 0.92 (s, 3H, 18-CH₃); MS (EI): m/z 324 (M⁺).

(b) Preparation of [17(20)Z]-Propylideneestra-1,3,5(10)-triene-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**32**):

Using the procedure of Example 8, part (f), there was obtained from 3-hydroxy-[17(20)Z]-propylidene-estra-1,3,5(10)-triene-2-carboxaldehyde (**25**, 0.195 g, 0.6 mmol) after chromatography (n-hexane:EtOAc, 15:1-10:1, v/v) 0.163 g of **32** (71% yield), m.p. 140-142°C.

¹H NMR: δ 8.58 (s, 1H, -CH=N-), 7.53 (s, 1H, aromatic), 6.99 (s, 1H, aromatic), 5.22-5.00 (m, 1H, =CH-CH₂-), 0.97 (t, 3H, 23-CH₃), 0.92 (s, 3H, 18-CH₃); MS (EI): *m/z* 385 (M⁺). HRMS calcd. for C₂₂H₂₈N₁O₃S₁, 386.1790; found, 386.1795.

Example 11

Preparation of [17(20)Z]-19,21-Dinorchola-1,3,5(10),17(20)-tetraeno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**33**)

(a) Preparation of 3-hydroxy-[17(20)Z]-19,21-dinorchola-1,3,5(10),17(20)-tetraene-2-carboxaldehyde (**26**):

Using the procedures of Example 8, part (e), there was obtained from [17(20)Z]-19,21-dinorchola-1,3,5(10),17(20)-tetraen-3-ol (**22**, 1.24 g, 4.0 mmol) after chromatography (n-hexane:AcOEt, 30:1-5:1, v/v) 1.19 g of **26** (88% yield).

¹H NMR: δ 10.79 (s, 1H, -OH), 9.83 (s, 1H, -CHO), 7.43 (s, 1H, aromatic), 6.71 (s, 1H, aromatic), 5.17-5.02 (m, 1H, =CH-CH₂-), 0.93 (t, 3H, 24-CH₃), 0.93 (s, 3H, 18-CH₃); MS (EI): *m/z* 338 (M⁺).

(b) Preparation of [17(20)Z]-19,21-dinorchola-1,3,5(10),17(20)-tetraeno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**33**):

Using the procedures of Example 8, part (f), there was obtained from 3-hydroxy-[17(20)Z]-19,21-dinorchola-1,3,5(10),17(20)-tetraene-2-carboxaldehyde (**26**, 0.169 g, 0.5 mmol) after chromatography (n-hexane:EtOAc, 20:1-5:1, v/v) 0.107 g of **33** (53% yield), m.p. 163°C.

¹H NMR: δ 8.58 (s, 1H, -CH=N-), 7.53 (s, 1H, aromatic), 6.99 (s, 1H, aromatic), 5.15-5.00 (m, 1H, =CH-CH₂-), 0.92 (t, 3H, 24-CH₃), 0.92 (s, 3H, 18-CH₃); MS (EI): *m/z* 399 (M⁺). HRMS calcd. for C₂₃H₃₀N₁O₃S₁, 400.1946; found, 400.1925.

Example 12

Preparation of 17β-Methylestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**34**)

(a) Synthesis of 3-hydroxy-17β-methylestra-1,3,5(10)-triene-2-carboxaldehyde (**27**):

To a solution of 3-hydroxy-17-methylene-estra-1,3,5(10)-triene-2-carboxaldehyde (**23**, 0.401 g, 1.35 mmol) in EtOAc (10 mL) was added 10% palladium on carbon (0.060 g). The reaction mixture

was stirred for 4 h under the hydrogen atmosphere at room temperature. After the catalyst was filtered, the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (10:1–2:1, v/v) to afford 0.307 g of **27** (76% yield).

¹H NMR: δ 10.77 (s, 1H, -OH), 9.82 (s, 1H, -CHO), 7.43 (s, 1H, aromatic), 6.70 (s, 1H, aromatic), 0.88 (d, 3H, 20-CH₃), 0.60 (s, 3H, 18-CH₃).

(b) Synthesis of 17 β -methylestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**34**):

By the procedure described in Example 8, part (f), there was obtained from 3-hydroxy-17 β -methyl-estra-1,3,5(10)-triene-2-carboxaldehyde (**27**, 0.298 g, 1.0 mmol) after chromatography (n-hexane:EtOAc, 10:1–5:1, v/v) 0.181 g of **34** (50% yield), m.p. 194–196°C.

¹H NMR: δ 8.58 (s, 1H, -CH=N-), 7.54 (s, 1H, aromatic), 6.98 (s, 1H, aromatic), 0.89 (d, 3H, 20-CH₃), 0.60 (s, 3H, 18-CH₃); MS (DCI): *m/z* 377 (M⁺+NH₄), 360 (M⁺+H). HRMS calcd. for C₂₀H₂₆N₁O₃S₁, 360.1633; found, 360.1657.

Example 13

Preparation of 17 β -Propylestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**35**)

(a) Synthesis of 3-hydroxy-17 β -propylestra-1,3,5(10)-triene-2-carboxaldehyde (**28**): Using the procedure of Example 12, part (a), there was obtained from 3-hydroxy-[17(20)Z]-propylideneestra-1,3,5(10)-triene-2-carboxaldehyde (**25**, 0.714 g, 2.20 mmol) after chromatography (n-hexane:AcOEt, 30:1–10:1, v/v) 0.489 g of **28** (68% yield), m.p. 122–123°C.

¹H NMR: δ 10.77 (s, 1H, -OH), 9.81 (s, 1H, -CHO), 7.42 (s, 1H, aromatic), 6.69 (s, 1H, aromatic), 0.91 (t, 3H, 23-CH₃), 0.62 (s, 3H, 18-CH₃); MS (EI): *m/z* 326 (M⁺).

(b) Preparation of 17 β -propylestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**36**):

Using the procedure in Example 8, part (f), there was obtained from 3-hydroxy-17 β -propylestra-1,3,5(10)-triene-2-carboxaldehyde (**28**, 0.196 g, 0.6 mmol) after chromatography (n-hexane:EtOAc, 15:1–10:1, v/v) 0.206 g of **35** (89% yield), m.p. 167–169°C.

¹H NMR: δ 8.57 (s, 1H, -CH=N-), 7.53 (s, 1H, aromatic), 6.98 (s, 1H, aromatic), 0.92 (t, 3H, 23-CH₃), 0.62 (s, 3H, 18-CH₃); MS (EI): *m/z* 387 (M⁺). HRMS calcd. for C₂₂H₃₀N₁O₃S₁, 388.1946; found, 388.1967.

Example 14Preparation of 17 β -Propylestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (36)

(a) Synthesis of 3-hydroxy-17 β -19,21-dinorchola-1,3,5(10)-triene-2-carboxaldehyde (29):


Using the procedure of Example 12, part (a), there was obtained from 3-hydroxy-[17(20)Z]-19,21-dinorchola-1,3,5(10),17(20)-tetraene-2-carboxaldehyde (26, 0.580g, 1.71 mmol) after chromatography (n-hexane:AcOEt, 30:1-1:1, v/v) 0.341 g of 29 (59% yield). m.p. 102-103°C.

¹H NMR: δ 10.77 (s, 1H, -OH), 9.81 (s, 1H, -CHO), 7.42 (s, 1H, aromatic), 6.69 (s, 1H, aromatic), 0.90 (t, 3H, 24-CH₃), 0.62 (s, 3H, 18-CH₃); MS (EI): *m/z* 340 (M⁺).

(b) Preparation of 17 β -19,21-dinorchola-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (36):

Using the procedure of Example 8, part (f), there was obtained from 3-hydroxy-17 β -19,21-dinorchola-1,3,5(10)-triene-2-carboxaldehyde (29, 0.170 g, 0.5 mmol) after chromatography (n-hexane:EtOAc, 15:1-10:1, v/v) 0.125 g of 36 (62% yield), m.p. 155-156°C.

¹H NMR: δ 8.57 (s, 1H, -CH=N-), 7.53 (s, 1H, aromatic), 6.98 (s, 1H, aromatic), 0.90 (t, 3H, 24-CH₃), 0.62 (s, 3H, 18-CH₃); MS (EI): *m/z* 401 (M⁺). HRMS calcd. for C₂₃H₃₂N₁O₃S₁, 402.2103; found, 402.2100.

Example 15Preparation of 19-Norpregna-1,3,5(10),17(20),20-pentaeno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (40)Scheme 9

SUBSTITUTE SHEET (RULE 26)

(a) Synthesis of 3-hydroxy-19-norpregna-1,3,5(10),17(20),20-pentaene (**38**):

To a solution of ethynylestradiol (**37**, 10.37 g, 35 mmol) in THF (500 mL) was added diisobutylaluminum hydride (245 mL, 1.0 M solution in toluene), and stirred for 24 h at reflux. The reaction mixture was quenched with MeOH at 0°C and added saturated aqueous NaCl (ca 200 mL). The supernatant was decanted, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using CHCl₃:THF (20:1-10:1, v/v) to afford 7.56 g of **38** (77% yield), m.p. 113-115°C.

¹H NMR: δ 7.17 (d, 1H, aromatic), 6.72-6.53 (m, 2H, aromatic), 5.05-4.85 (s, 1H, -OH), 4.80-4.63 (m, 2H, =C=CH₂), 0.91 (s, 3H, 18-CH₃).

(b) Synthesis of 3-hydroxy-19-norpregna-1,3,5(10),17(20),20-pentaene-2-carboxaldehyde (**39**):

To a suspension of magnesium (0.250 g, 10.0 mmol) in THF (2.5 mL) was added bromoethane (1.1 mL, 14 mmol) dissolved in THF (2.5 mL) at room temperature. 3-Hydroxy-19-norpregna-1,3,5(10),17(20),20-pentaene (**38**, 0.560 g, 2.0 mmol) dissolved in THF (5.0 mL) was added to the reaction mixture, and stirring continued for 30 min. The solvent was removed at reduced pressure, and to the residue were added benzene (25 mL), hexamethylphosphoric triamide (0.95 mL, 5.0 mmol) and paraformaldehyde (0.830 g). Stirring was continued for 3 h at 80°C. After the reaction mixture was cooled to room temperature, 5 N HCl (10 mL) was added and the mixture extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:AcOEt (20:1-10:1, v/v) to afford 0.530 g of **39** (86% yield), m.p. 97-99°C.

¹H NMR: δ 10.78 (s, 1H, -OH), 9.82 (s, 1H, -CHO), 7.43 (s, 1H, aromatic), 6.70 (s, 1H, aromatic), 4.83-4.65 (m, 2H, =C=CH₂), 0.91 (s, 3H, 18-CH₃); MS (EI): *m/z* 308 (M⁺).


(c) Synthesis of 19-norpregna-1,3,5(10),17(20),20-pentaeno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**40**):

To a solution of chlorosulfonyl isocyanate (0.23 mL, 2.5 mmol) in CH₂Cl₂ (1.0 mL) was added formic acid (0.5 mL of a CH₂Cl₂ solution, 5.0 M, 2.5 mmol) at 0°C. The reaction mixture was warmed to room temperature and stirred for 1 h. To a solution of 3-hydroxy-19-norpregna-1,3,5(10),17(20),20-pentaene-2-carboxaldehyde (**39**, 0.154 g, 0.5 mmol) in DMF (3.0 mL) was added sodium hydride (0.100 g of a mineral oil dispersion, 60%, 3.0 mmol) at 0°C. The reaction mixture was stirred for 1 h, the pre-prepared reagent was added, and stirring continued for 2 h at 0°C and additional 1 h at room

temperature. The reaction mixture was quenched with saturated aqueous NH_4Cl at 0°C and extracted with EtOAc. The combined organic layers were washed with H_2O , then with saturated aqueous NaCl, and dried (Na_2SO_4). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (15:1–10:1, v/v) to afford 0.148 g of **40** (80% yield), m.p. $133\text{--}135^\circ\text{C}$.

^1H NMR: δ 8.58 (s, 1H, $-\text{CH}=\text{N}-$), 7.54 (s, 1H, aromatic), 6.99 (s, 1H, aromatic), 4.88–4.65 (m, 1H, $=\text{C}=\text{CH}_2$), 0.91 (s, 3H, 18-CH_3); MS (EI): m/z 369 (M^+). HRMS calcd. for $\text{C}_{21}\text{H}_{24}\text{N}_1\text{O}_3\text{S}_1$, 370.1477; found, 370.1494.

Example 16



Scheme 10

(a) Preparation of 3-hydroxy-17β-methoxyestra-1,3,5(10)-triene-2-carboxaldehyde (**42**):

To a suspension of magnesium (0.110 g 4.5 mmol) in THF (1.0 mL) was added bromoethane (0.50 mL, 6.6 mmol) dissolved in THF (1.0 mL) at room temperature. 3-Hydroxy-17β-methoxyestra-1,3,5(10)-triene (**41**, 0.258 g, 0.90 mmol; synthesized by the method of Coombs et al., *Steroids* 6(6):841–844 (1965)), dissolved in THF (3.0 mL) was added to the reaction mixture, and stirring continued for 30 min. The solvent was removed at reduced pressure, and to the residue were added benzene (10 mL, hexamethylphosphoric triamide (0.40 mL, 2.1 mmol) and paraformaldehyde (0.370 g). Stirring was continued for 2 h at 80°C . After the reaction mixture was cooled to room temperature, 5 N HCl (5.0 mL) was added and the mixture extracted with EtOAc. The combined organic layers were washed with H_2O , then with saturated aqueous NaCl, and dried (Na_2SO_4). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:AcOEt (10:1–8:1, v/v) to afford 0.221 g of **42** (78% yield), m.p. $120\text{--}121^\circ\text{C}$.

^1H NMR: δ 10.77 (s, 1H, -OH), 9.81 (s, 1H, -CHO), 7.42 (s, 1H, aromatic), 6.70 (s, 1H, aromatic), 3.38 (s, 3H, 17 β -OCH₃), 3.32 (t, 1H, 17 α -H), 0.80 (s, 3H, 18-CH₃). MS (EI): m/z 314 (M⁺).

(b) Preparation of 17 β -methoxyestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide
5 (43):

To a solution of chlorosulfonyl isocyanate (0.23 mL, 2.5 mmol) in CH₂Cl₂ (1.0 mL) was added formic acid (0.5 mL of a CH₂Cl₂ solution, 5.0 M, 2.5 mmol) at 0°C. The reaction mixture was warmed to room temperature and stirred for 1 h. To a solution of 3-hydroxy-17 β -methoxyestra-1,3,5(10)-triene-2-carboxaldehyde (42, 0.157 g, 0.5 mmol) in DMF (3.0 mL) was added sodium
10 hydride (0.100 g of a mineral oil dispersion, 60%, 3.0 mmol) at 0°C. The reaction mixture was stirred for 1 h, the pre-prepared reagent was added, and stirring continued for 3 h at 0°C. The reaction mixture was quenched with saturated aqueous NH₄Cl at 0°C and extracted with EtOAc. The combined organic layers were washed with H₂O, then with saturated aqueous NaCl, and dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The
15 residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (3:1-2:1, v/v) to afford 0.087 g of the starting material 42 (55% yield) and 0.074 g of 43 (39% yield), m.p. 172-173°C.

^1H NMR: δ 8.57 (s, 1H, -CH=N-), 6.99 (s, 1H, aromatic), 6.99 (s, 1H, aromatic), 3.38 (s, 3H, 17 β -OCH₃), 3.33 (t, 1H, 17 α -H), 0.80 (s, 3H, 18-CH₃); MS (EI): m/z 375 (M⁺). HRMS calcd. for C₂₀H₂₆N₁O₄S₁, 376.1583; found, 376.1603.

Example 17Preparation of[17(20)E]-Propylideneestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2,2'-dioxide (49)


5

10

15

20

25

Scheme 11(a) Synthesis of 3-*tert*-butyldimethylsilyloxy-17 α -ethenylestra-1,3,5(10)-trien-17 β -ol (45):

30

To a solution of 17 α -ethenylestradiol (44, 0.298 g, 1.0 mmol) in CH₂Cl₂ (5.0 mL) and THF (1.0 mL) were added triethylamine (0.35 mL, 2.5 mmol), *tert*-butyldimethylchlorosilane (0.226 g, 1.5 mmol) and 4-dimethylaminopyridine (0.0006 g, 0.05 mmol) at room temperature. The reaction mixture was stirred for 2 days, diluted with EtOAc, washed with H₂O, saturated aqueous NaCl, and then dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure.

The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (5:1=3:1, v/v) to afford 0.358 g of **45** (87% yield), m.p. 127-128°C.

¹H NMR: δ 7.10 (d, 1H, aromatic), 6.67-6.52 (m, 2H, aromatic), 6.12 (dd, 1H, CH=CH₂), 5.25-5.13 (m, 2H, -CH=CH₂), 0.97 (s, 9H, -C(CH₃)₃), 0.95 (s, 3H, 18-CH₃), 0.18 (s, 6H, -Si(CH₃)₂).

5 (b) Synthesis of 3-*tert*-butyldimethylsilyloxy-[17(20)E]-propylideneestra-1,3,5(10)-triene (**46**):

To a solution of phosphorous tribromide (4.5 mL of a CH₂Cl₂ solution, 1.0 M, 4.5 mmol) in toluene (6.0 mL) was added a solution of 3-*tert*-butyldimethylsilyloxy-17α-ethenylestra-1,3,5(10)-trien-17β-ol (**45**, 1.86 g, 4.5 mmol) and pyridine (0.40 mL, 5.0 mmol) in toluene (25 mL) at 0°C. The reaction mixture was stirred for 2 h, quenched with H₂O and extracted with EtOAc. The combined
10 organic layers were washed with H₂O, saturated aqueous NaCl, and then dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was dissolved in THF (20 mL) and added methylmagnesiumbromide (7.5 mL of a Et₂O solution, 3.0 M, 22.5 mmol) at 0°C. The reaction mixture was stirred for 19 h at room temperature, and quenched with H₂O at 0°C and extracted with EtOAc. The combined organic layers were washed with H₂O, saturated aqueous NaCl,
15 and then dried (Na₂SO₄). The residue was purified by column chromatography (silica gel) using n-hexane:CHCl₃ (5:1=3:1, v/v) to afford 1.06 g of **46** (57% yield), m.p. 59-60°C.

¹H NMR: δ 7.13 (d, 1H, aromatic), 6.66-6.51 (m, 2H, aromatic), 5.08-4.95 (m, 1H, =CHCH₂), 0.98 (s, 9H, -C(CH₃)₃), 0.93 (t, 3H, 23-CH₃), 0.78 (s, 3H, 18-CH₃), 0.18 (s, 6H, -Si(CH₃)₂).

(c) Synthesis of [17(20)E]-propylideneestra-1,3,5(10)-trien-3-ol (**47**):

20 To a solution of 3-*tert*-butyldimethylsilyloxy-[17(20)E]-propylideneestra-1,3,5(10)-triene (**46**, 0.821 g, 2.0 mmol) in THF (20 mL) was added tetrabutylammonium fluoride (2.4 mL of a THF solution, 1.0 M, 2.4 mmol) at 0°C. The reaction mixture was stirred for 1h, diluted with EtOAc, washed with H₂O, saturated aqueous NaCl, and then dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography
25 (silica gel) using n-hexane:EtOAc (10:1=5:1, v/v) to afford 0.598 g of **47** (100% yield), m.p. 105-106°C.

¹H NMR: δ 7.17 (d, 1H, aromatic), 6.67-6.52 (m, 2H, aromatic), 5.06-4.95 (m, 1H, =CHCH₂), 4.53 (s, 1H, -OH), 0.95 (t, 3H, 23-CH₃), 0.78 (s, 3H, 18-CH₃); MS (EI): *m/z* 296 (M⁺).

(d) Synthesis of 3-hydroxy-[17(20)E]-propylideneestra-1,3,5(10)-triene-2-carboxaldehyde

30 (**48**):
To a suspension of magnesium (0.123 g, 5.0 mmol) in THF (1.5 mL) was added bromoethane (0.53 mL, 7.0 mmol) dissolved in THF (1.5 mL) at room temperature. [17(20)E]-Propylideneestra-1,3,5(10)-trien-3-ol (**47**, 0.297 g, 1.0 mmol) dissolved in THF (3.0 mL) was added to the reaction mixture, and stirring was continued for 30 min. The solvent was removed at reduced pressure. To the

residue were added benzene (10 mL), hexamethylphosphoric triamide (0.46 mL, 2.5 mmol) and paraformaldehyde (0.410 g). Stirring was continued for 1 h at 80°C. After the reaction mixture was cooled to room temperature, 1 N HCl (5.0 mL) was added and the mixture extracted with EtOAc. The combined organic layers were washed with H₂O, saturated aqueous NaCl, and then dried (Na₂SO₄).

5 The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (30:1=15:1, v/v) to afford 0.319 g of **48** (98% yield).


¹H NMR: δ 10.77 (s, 1H, -OH), 9.82 (s, 1H, -CHO), 7.44 (s, 1H, aromatic), 6.70 (s, 1H, aromatic), 5.06-4.98 (m, 1H, =CHCH₂), 0.96 (t, 3H, 23-CH₃), 0.79 (s, 3H, 18-CH₃); MS (EI): *m/z* 324 (M⁺).

10 (e) Synthesis of [17(20)E]-propylideneestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2,2'-dioxide (**49**):

To a solution of chlorosulfonyl isocyanate (0.32 mL, 3.5 mmol) in CH₂Cl₂ (1.2 mL) was added formic acid (0.7 mL of a CH₂Cl₂ solution, 5.0 M, 3.5 mmol) at 0°C. The reaction mixture was warmed to room temperature and stirred for 1h. To a solution 3-hydroxy - [17(20)E]-propylideneestra-1,3,5(10)-triene-2-carboxaldehyde (**48**, 0.227 g, 0.70 mmol) in DMF (4.0 mL) was added sodium hydride (0.140 g of a mineral oil dispersion, 60%, 3.5 mmol) at 0°C. The reaction mixture was stirred for 1 h, the chlorosulfonyl isocyanate in formic acid was added, and stirring continued for 4 h at 0°C. The reaction mixture was quenched with saturated aqueous NH₄Cl at 0°C and extracted with EtOAc.

20 The combined organic layers were washed with H₂O, saturated aqueous NaCl, and then dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (10:1=5:1, v/v) to afford 0.056 g of the starting material **48** (25% yield) and 0.145 g of **49** (54% yield), m.p. 170-171°C.

25 ¹H NMR: δ 8.58 (s, 1H, -CH=N-), 7.55 (s, 1H, aromatic), 6.99 (s, 1H, aromatic), 5.10-4.97 (m, 1H, =CHCH₂), 0.96 (t, 3H, 23-CH₃), 0.79 (s, 3H, 18-CH₃); MS (EI): *m/z* 385 (M⁺).

Example 18Preparation of [17(20)E]-Carbethoxy-
methylideneestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (54)Scheme 12

(a) Synthesis of 3-*tert*-butyldimethylsilyl-oxyestra-1,3,5(10)-trien-17-one (50):

To a solution of estrone (18, 8.10 g, 30.0 mmol) in DMF (25 mL) were added imidazole (3.07 g, 45 mmol) and *tert*-butyldimethylchlorosilane (5.42 g, 36 mmol) at room temperature. The reaction mixture was stirred for 18 h and then quenched with H_2O (100 mL). The precipitate was collected by filtration and washed with H_2O to afford 11.4 g of 50 (99% yield), m.p. 171-172°C.

^1H NMR: δ 7.12 (d, 1H, aromatic), 6.67-6.55 (m, 2H, aromatic), 0.98 (s, 9H, $-\text{C}(\text{CH}_3)_3$), 0.91 (s, 3H, 18- CH_3), 0.19 (s, 6H, $-\text{Si}(\text{CH}_3)_2$).

SUBSTITUTE SHEET (RULE 26)

(b) Synthesis of ethyl 3-*tert*-butyldimethylsilyloxy-[17(20)Z]-19-norpregna-1,3,5(10),17(20)-tetraen-21-oate (**51a**) and ethyl 3-*tert*-butyldimethylsilyloxy-[17(20)E]-19-norpregna-1,3,5(10),17(20)-tetraen-21-oate (**51b**):

To a solution of triethylphosphonoacetate (3.17 mL, 16 mmol) in THF (40 mL) was added potassium *tert*-butoxide (1.68 g, 15 mmol) at room temperature. The reaction mixture was stirred for 30 min, and 3-*tert*-butyldimethylsilyloxyestra-1,3,5(10)-trien-17-one (**50**, 1.92 g, 5.0 mmol) was added. The stirring continued for 2 days at reflux. The reaction mixture was cooled to room temperature and quenched with saturated aqueous NH₄Cl followed by extraction with EtOAc. The combined organic layers were washed with H₂O, saturated aqueous NaCl, and then dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (40:1=30:1, v/v) to afford 0.473 g of **51a** (21% yield) and 1.26 g of **51b** (55% yield), m.p. 109-110°C.

51a: ¹H NMR: δ 7.12 (d, 1H, aromatic), 6.65-6.50 (m, 2H, aromatic), 5.70-5.63 (m, 1H, =CH-COOEt), 4.23-4.05 (m, 2H, -COOCH₂CH₃), 1.29 (t, 3H, -COOCH₂CH₃), 1.04 (s, 3H, 18-CH₃), 0.98 (s, 9H, -C(CH₃)₃), 0.18 (s, 6H, -Si(CH₃)₂).

51b: ¹H NMR: δ 7.12 (d, 1H, aromatic), 6.65-6.50 (m, 2H, aromatic), 5.59 (s, 1H, =CH-COOEt), 4.16 (q, 2H, -COOCH₂CH₃), 1.29 (t, 3H, -COOCH₂CH₃), 0.98 (s, 9H, -C(CH₃)₃), 0.86 (s, 3H, 18-CH₃), 0.19 (s, 6H, -Si(CH₃)₂).

(c) Synthesis of ethyl 3-hydroxy-[17(20)E]-19-norpregna-1,3,5(10),17(20)-tetraen-21-oate (**52**):

To a solution of ethyl 3-*tert*-butyldimethylsilyloxy-[17(20)E]-19-norpregna-1,3,5(10),17(20)-tetraen-21-oate (**51b**, 1.00 g, 2.2 mmol) in THF (15 mL) was added tetrabutylammonium fluoride (2.5 mL of a THF solution, 1.0 M, 2.5 mmol) at 0°C. The reaction mixture was stirred for 1 h, diluted with EtOAc, washed with H₂O, saturated aqueous NaCl, and then dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (5:1=3:1, v/v) to afford 0.727 g of **52** (97% yield), m.p. 153-154°C.

¹H NMR: δ 7.15 (d, 1H, aromatic), 6.68-6.53 (m, 2H, aromatic), 5.59 (s, 1H, =CH-COOEt), 4.77-4.65 (m, 1H, -OH), 4.17 (q, 2H, -COOCH₂CH₃), 1.29 (t, 3H, -COOCH₂CH₃), 0.86 (s, 3H, 18-CH₃); MS (EI): *m/z* 340 (M⁺).

(d) Synthesis of ethyl 2-formyl-3-hydroxy-[17(20)E]-19-norpregna-1,3,5(10),17(20)-tetraen-21-oate (**53**):

To a solution of ethyl 3-hydroxy-[17(20)E]-19-norpregna-1,3,5(10),17(20)-tetraen-21-oate (**53**, 0.681 g, 2.0 mmol) in 1,2-dichloroethane (15 mL) and toluene (7.0 mL) were added 2, 6-lutidine


(0.12 ml, 10 mmol) and tin (IV) chloride (0.4 mL of a n-heptane solution, 1.0 M, 0.4 mmol), and the mixture was stirred for 30 min at room temperature. To the reaction mixture was added paraformaldehyde (200 mg) and stirring was continued for 18 h at 100°C. After the reaction mixture was cooled to room temperature, 1 N HCl (20 mL) was added and the mixture extracted with EtOAc. The combined organic layers were washed with H₂O, saturated aqueous NaCl, and then dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (7:1=5:1, v/v) to afford 0.224 g of **53** (30% yield), m.p. 135-136°C.

¹H NMR: δ 10.78 (s, 1H, -OH), 9.82 (s, 1H, -CHO), 7.43 (s, 1H, aromatic), 6.71 (s, 1H, aromatic), 5.60 (s, 1H, =CH-COOEt), 4.17 (q, 2H, -COOCH₂CH₃), 1.30 (t, 3H, -COOCH₂CH₃), 0.88 (s, 3H, 18-CH₃); MS (EI): *m/z* 368 (M⁺).

(e) Synthesis of [17(20)E]-carbethoxy-methylideneestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**54**):

To a solution of chlorosulfonyl isocyanate (0.14 mL, 1.5 mmol) in CH₂Cl₂ (0.6 mL) was added formic acid (0.3 mL of a CH₂Cl₂ solution, 5.0 M, 1.5 mmol) at 0°C. The reaction mixture was warmed to room temperature and stirred for 1 h. To a solution ethyl 2-formyl-3-hydroxy-[17(20)E]-19-norpregna-1,3,5(10),17(20)-tetraen-21-oate (**53**, 0.110 g, 0.30 mmol) in DMF (3.0 mL) was added sodium hydride (0.060 g of a mineral oil dispersion, 60%, 1.5 mmol) at 0°C. The reaction mixture was stirred for 1 h, the chlorosulfonyl isocyanate in formic acid was added, and stirring continued for 2 h at 0°C. The reaction mixture was quenched with saturated aqueous NH₄Cl at 0°C and extracted with EtOAc. The combined organic layers were washed with H₂O, saturated aqueous NaCl, and then dried (Na₂SO₄). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:EtOAc (5:1=3:1, v/v) to afford 0.057 g of the starting material **53** (52% yield) and 0.043 g of **54** (33% yield), m.p. 223-224°C.

¹H NMR: δ 8.58 (s, 1H, -CH=N-), 7.54 (s, 1H, aromatic), 7.00 (s, 1H, aromatic), 5.61 (s, 1H, =CH-COOEt), 4.17 (q, 2H, -COOCH₂CH₃), 1.30 (t, 3H, -COOCH₂CH₃), 0.88 (s, 3H, 18-CH₃); MS (EI): *m/z* 429 (M⁺).

Example 19Preparation of17-Dicyanomethylideneestra-1,3,5(10)-trieno-
[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (66)Scheme 13

(a) Synthesis of 20-cyano-3-hydroxy-19-norpregna-1,3,5(10),17(20)-tetraene-21-nitrile (55):

To a suspension of estrone (18, 1.35 g, 5.0 mmol) in benzene (35 mL) and acetic acid (5.0 mL) were added malononitrile (1.65 g, 40 mmol) and β -alanine (0.535 g, 6.0 mmol), and stirring was continued for 19 h at reflux. After the reaction mixture was cooled to room temperature, H_2O was added and the reaction mixture extracted with EtOAc. The combined organic layers were washed with H_2O , saturated aqueous NaCl, and then dried (Na_2SO_4). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was washed with Et_2O to afford 1.46 g of 55 (92% yield). m.p. > 250°C.

^1H NMR: δ 7.13 (d, 1H, aromatic), 6.70-6.53 (m, 2H, aromatic), 1.07 (s, 3H, 18- CH_3); MS (EI): m/z 318 (M^+).

(b) Synthesis of 20-cyano-2-formyl-3-hydroxy-19-norpregna-1,3,5(10),17(20)-tetraene-21-nitrile (56):

To a solution of 20-cyano-3-hydroxy-19-norpregna-1,3,5(10),17(20)-tetraene-21-nitrile (**55**, 0.637 g, 2.0 mmol) in CH_2Cl_2 (15 mL) and toluene (7.0 mL) were added 2,6-lutidine (0.12 mL, 1.0 mmol) and tin (IV) chloride (0.4 mL of a n-heptane solution, 1.0 M, 0.4 mmol), and stirring was continued for 30 min at room temperature. To the reaction mixture was added paraformaldehyde (200 mg) and stirring continued for 18 h at 100°C. After the reaction mixture was cooled to room temperature, 1 N HCl (20 mL) was added and the mixture extracted with EtOAc. The combined organic layers were washed with H_2O , saturated aqueous NaCl, and then dried (Na_2SO_4). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:THF (5:1=3:1, v/v) to afford 0.313 g of **56** (45% yield), m.p. > 250°C.

^1H NMR: δ 10.81 (s, 1H, -OH), 9.84 (s, 1H, -CHO), 7.41 (d, 1H, aromatic), 6.72 (s, 1H, aromatic), 1.09 (s, 3H, 18- CH_3); MS (EI): m/z 346 (M^+).

(c) Synthesis of 17-dicyanomethylideneestra-1,3,5(10)-trieno-[3,2,e]-1',2',3'-oxathiazine-2',2'-dioxide (**57**):

To a solution of chlorosulfonyl isocyanate (0.14 mL, 1.5 mmol) in CH_2Cl_2 (0.6 mL) was added formic acid (0.3 mL of a CH_2Cl_2 solution, 5.0 M, 1.5 mmol) at 0°C. The reaction mixture was warmed to room temperature and stirred for 1 h. To a solution of 20-cyano-2-formyl-3-hydroxy-19-norpregna-1,3,5(10),17(20)-tetraene-21-nitrile (**56**, 0.104 g, 0.30 mmol) in DMF (3.0 mL) was added sodium hydride (0.060 g of a mineral oil dispersion, 60%, 1.5 mmol) at 0°C. The reaction mixture was stirred for 1 h, the chlorosulfonyl isocyanate in formic acid was added, and stirring continued for 3 h at 0°C. The reaction mixture was quenched with saturated aqueous NH_4Cl at 0°C and extracted with EtOAc. The combined organic layers were washed with H_2O , saturated aqueous NaCl, and then dried (Na_2SO_4). The desiccant was filtered and the solvent was evaporated at reduced pressure. The residue was purified by column chromatography (silica gel) using n-hexane:THF (5:1=2:1, v/v) to afford 0.040 g of the starting material **65** (39% yield) and 0.027 g of **66** (22% yield), m.p. > 250°C.

^1H NMR: δ 8.61 (s, 1H, - $\text{CH}=\text{N}-$), 7.53 (s, 1H, aromatic), 7.02 (s, 1H, aromatic), 1.10 (s, 3H, 18- CH_3); MS (EI): m/z 407 (M^+).

Example 20

Biological Evaluation: Procedures and Results

A. Procedures:

Test for the Effects of Inhibitors on Estrone Sulfatase Activity in MCF-7 Cells:

Reagents: MCF-7 human breast cancer cells were supplied by the American Type Culture Collection, Rockville, MD. Eagle's minimum essential medium (MEM) and fetal calf serum (FCS)

were purchased from Sigma Chemical Company, St. Louis, MO. [4-¹⁴C] Estrone, [6,7-³H] estradiol and [6,7-³H(N)] estrone sulfate were obtained from New England Nuclear Research Products, Boston, MA.

Estrone Sulfatase Assay with Intact Cells. The procedure of Duncan et al., Cancer Res. 53:298-303 (1993) was followed. MCF-7 cells were seeded in 60 x 15 mm culture dishes at 1×10^5 cells/dish and maintained in 4.0 mL of MEM containing 2mM of glutamine and 5% of FCS. The cells were incubated at 37°C in a 5% CO₂/95% air atmosphere and 100% humidity, with the medium changed every third day. When the cells reach 80% confluency, the intact monolayers were washed once with Earl's balanced salt solution and incubated in 4.0 mL of serum-free MEM containing the substrate (³H-estrone sulfate, 7 pmol, 9×10^5 dpm) and inhibitor dissolved in ethanol or ethanol alone. The final ethanol concentration was always be below 1%. The incubation continued for 24 h. 2.0 mL of medium was transferred into separate tubes containing 7×10^3 dpm of ¹⁴C-estrone. The mixture was vortexed vigorously for 60 s with 5 mL of toluene. After phase separation, 2.0 mL of the organic phase was transferred into a counting vial for scintillation counting. The amount of estrone sulfate hydrolyzed was calculated on the basis of the ³H counts obtained, with the added ¹⁴C-estrone used to correct for recovery through the extraction procedure.

The cells remaining in each culture dish were washed with saline once and then scraped with 1.0 mL of 0.5 N NaOH into 10 x 75 mm tubes. The cell pellets in each tube were incubated at 50°C for 20 min. to ensure that digestion was complete and that all proteins became soluble. An aliquot was then taken for protein determination by Lowry's method (Lowry et al., J. Biol. Chem. 193:265-275 (1951)).

The amount of estrone sulfate hydrolyzed with the inhibitor relative to that without the inhibitor was evaluated to give the percentage of inhibition.

In Vivo Efficacy Studies Using MCF-7 Cells in Nude Mice:

For *in vivo* evaluation, human xenografts were used in nude (athymic) mice, in the context of a solid tumor assay.

MCF-7 human breast carcinomas in nude mice were used as the model for evaluating the estrone sulfatase inhibitors. The protocol followed was essentially that of Yue et al., J. Steroid Biochem. 44:671-673 (1993). Because MCF-7 cells are known to require supplementation with estradiol to sustain progressive growth in athymic nude mice (Soule et al., Cancer Lett. 10:177-189 (1980)), estrone sulfate was used for supplemental estrogen in the model studies. The enzyme inhibitors were administered by intravenous injection, oral gavage, and intraperitoneal administration, and comparative efficacy of the various compounds were evaluated using these different routes.

Materials:

Female BALB/c athymic mice 4-6 weeks of age were supplied by Charles River Breeding Laboratories, Boston, MA. MCF-7 cells for the *in vitro* cell growth inhibition assay were obtained from the American Type Culture Collection, Rockville, MD, and cultured under the same conditions as described above for the sulfatase assay.

Tumor Growth Inhibition Assay (see Santer et al. (1990), *supra*, Yue et al., *supra*, and Noel et al., Biochem. Pharmacol. 43:1263-1267 (1992):

The athymic mice were housed five per cage in controlled conditions of light and humidity and received food and water *ad libitum* throughout the entire experiment. The mice were quarantined for three working days before use in experiments. Prior to the initiation of the antitumor experiments, the mice were housed for seven days to familiarize them with the experimental environment. Temperature was maintained at $72 \pm 5^\circ\text{F}$, with relative humidity at 35-70% and a 12-h light/dark cycle. The mice were fed certified Purina rodent chow and drinking water *ad libitum*. The source water was recirculated, deionized, UV-treated, and filtered (5- μm filter).

At the beginning of the experiment, all but five of the mice underwent oophorectomies to eliminate the endogenous level of estrogen. After all animals recovered from surgery, all mice in the study received 5 μmol of estrone sulfate daily via gavage or subcutaneous (sc) injection. The dosing of estrone sulfate was carried out throughout the entire experiment. Seven days after the animals began treatment with estrone sulfate, each mouse was be injected sc twice (once in each flank) with 2.5×10^6 MCF-7 cells suspended in 0.1 mL of serum-free tissue culture medium to induce tumor growth. The growth rate was determined by measuring the tumors with calipers weekly. Tumor volumes were calculated according to the formula $\frac{4}{3}\pi r_1^2 r_2$, where r_1 and r_2 represent the tumor radii. When the average tumor volume per mouse reached approximately 200 mm^3 , animals began to receive various doses of estrone sulfatase inhibitors dissolved in 0.1 mL of phosphate buffered saline (PBS). Dosing was by oral gavage, intravenous injection, and intraperitoneal injection; daily dosing with estrone sulfatase inhibitors was continued throughout the remainder of the experiment. The estrone sulfatase inhibitors not soluble in aqueous solutions were dissolved in EtOH first and diluted with PBS to obtain the appropriate concentrations of inhibitor but keeping the concentration of EtOH below 1%.

For each test compound, the mice were divided into several groups with five animals in each group. These groups were as follows: intact control group receiving PBS alone; oophorectomized control group receiving PBS alone; and oophorectomized treatment groups receiving various doses of estrone sulfatase inhibitors.

The mice were treated with the estrone sulfatase inhibitors for 60 days, and the tumor growth rate was monitored weekly. The change in tumor volume in the treatment groups relative to that in the oophorectomized control group gave the percent inhibition of a given inhibitor.

Table 1		
EFFICACY OF ESTRONE SULFATASE INHIBITORS ON MCF-7 HUMAN BREAST CARCINOMA XENOGRAFTS IN ATHYMIC MICE ^a		
	Tumor Volume ^b	
Week	Compound 6	Control
0	133.6 ± 15.9	96.5 ± 5.2
1	185.8 ± 16.5	184.1 ± 26.3
2	191.3 ± 25.1	191.2 ± 36.1
3	181.8 ± 27.8	232.9 ± 46.4
4	234.0 ± 50.7	299.5 ± 54.3
5	285.8 ± 47.7	349.0 ± 46.2

^aMice were dosed by i.p. injection at 1.0 mg/mouse/day for 5 weeks.

^bMean ± S.E., mm³


Table 2: Estrone Sulfatase Inhibition Assay Results

Compound	Sulfatase Assay Concentration	Sulfatase Assay % Inhibition
<u>4</u>	12 nM	50
<u>6</u>	9.3 nM	50
<u>50</u>	20 nM	50
<u>50</u>	820 nM	50
<u>50</u>	44 nM	50
<u>14</u>	15 μ M	50
<u>50</u>	50 nM	50
<u>30</u>	72 nM	50
<u>31</u>	63 nM	50
<u>32</u>	58 nM	50
<u>33</u>	720 nM	50
<u>34</u>	45 nM	50
<u>30</u>	120 nM	50
<u>36</u>	590 nM	50
<u>40</u>	74 nM	50
<u>43</u>	50 nM	50

CLAIMS

1. A compound having the structural formula (I)

(I)



wherein:

n is 1 or 2;

R¹ and R² are different, and are selected from the group consisting of hydrogen, lower alkyl, lower alkynyl, and OR⁶ where R⁶ is hydrogen, lower alkyl or -(CO)-R⁷ where R⁷ is lower alkyl, or wherein R¹ and R² together form =O, =S, or =C(R⁸R⁹) in which R⁸ and R⁹ are independently selected from the group consisting of hydrogen, -CHO, lower alkyl, and cyano, or together form a =CH₂ substituent;

R³ is hydrogen, halogen or lower alkyl, or, when the dotted line at q₁ indicates the presence of a double bond, is CH₂;

R⁴ is selected from the group consisting of hydrogen and lower alkyl;

R⁵ is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, lower alkenyl, lower alkoxy, and aryl, or when the dotted line at q₂ indicates the presence of a double bond, is CH₂;

and either

X and Y are linked to form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring, if dihydro-oxathiazine, having a substituent R¹⁰ on the carbon atom adjacent to the A ring, wherein R¹⁰ is hydrogen, lower alkyl, lower alkynyl or monocyclic aryl, and Z is hydrogen, or

Y and Z are linked to form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring, if dihydro-oxathiazine, having a substituent R¹⁰ on the carbon atom adjacent to the A ring, wherein R¹⁰ is hydrogen, lower alkyl, lower alkynyl or monocyclic aryl, and X is hydrogen, cyano, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, nitro, -COOR¹¹, or -(CH₂)NR¹²R¹³ wherein R¹¹, R¹² and R¹³ are independently hydrogen or lower alkyl,

and pharmaceutically acceptable salts and esters thereof.

2. The compound of claim 1, wherein n is 1.

3. The compound of claim 1, wherein n is 2.

4. The compound of claim 1, wherein one of R^1 and R^2 is hydrogen, and the other is selected from the group consisting of hydroxyl, lower alkyl, lower alkoxy, lower acyl and ethynyl.

5. The compound of claim 1, wherein R^1 and R^2 together form $=O$ or $=C(R^8R^9)$ in which R^8 and R^9 are independently selected from the group consisting of hydrogen, $-CHO$, methyl, ethyl, n-propyl, and cyano, or together form a $=CH_2$ substituent.

6. The compound of any one of claims 1, 2, 3, 4 or 5, wherein X and Y are linked to form an oxathiazine dioxide ring.


7. The compound of claim 6, wherein R^{10} is hydrogen, methyl, ethynyl or phenyl.

8. The compound of any one of claims 1, 2, 3, 4 or 5, wherein Y and Z are linked to form an oxathiazine dioxide ring.

9. The compound of claim 8, wherein R^{10} is hydrogen, methyl, ethynyl or phenyl.

10. A method for inhibiting the enzymatic activity of estrone sulfatase comprising contacting the enzyme with an effective estrone sulfatase inhibiting amount of a compound having the structural formula (I)

(I)



wherein:

n is 1 or 2;

R¹ and R² are different, and are selected from the group consisting of hydrogen, lower alkyl, lower alkynyl, and OR⁶ where R⁶ is hydrogen, lower alkyl or -(CO)-R⁷ where R⁷ is lower alkyl, or
 5 wherein R¹ and R² together form =O, =S, or =C(R⁸R⁹) in which R⁸ and R⁹ are independently selected from the group consisting of hydrogen, -CHO, lower alkyl, and cyano, or together form a =CH₂ substituent;

R³ is hydrogen, halogen or lower alkyl, or, when the dotted line at q₁ indicates the presence of a double bond, is CH₂;

10 R⁴ is selected from the group consisting of hydrogen and lower alkyl;

R⁵ is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, lower alkenyl, lower alkoxy, and aryl, or when the dotted line at q₂ indicates the presence of a double bond, is CH₂; and either


X and Y are linked to form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring,
 15 if dihydro-oxathiazine, having a substituent R¹⁰ on the carbon atom adjacent to the A ring, wherein R¹⁰ is hydrogen, lower alkyl, lower alkynyl or monocyclic aryl, and Z is hydrogen, or

Y and Z are linked to form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring, if dihydro-oxathiazine, having a substituent R¹⁰ on the carbon atom adjacent to the A ring, wherein R¹⁰ is hydrogen, lower alkyl, lower alkynyl or monocyclic aryl, and X is hydrogen, cyano, lower alkyl,
 20 lower alkenyl, lower alkynyl, lower alkoxy, nitro, -COOR¹¹, or -(CH₂)NR¹²R¹³ wherein R¹¹, R¹² and R¹³ are independently hydrogen or lower alkyl,

or with a pharmaceutically acceptable salt or ester thereof.

11. A method for treating an individual with an estrogen-dependent disorder, comprising
 25 administering to the individual a pharmacologically effective amount of a compound of structural formula (I)

30 (I)



wherein:

n is 1 or 2;

R¹ and R² are different, and are selected from the group consisting of hydrogen, lower alkyl, lower alkynyl, and OR⁶ where R⁶ is hydrogen, lower alkyl or -(CO)-R⁷ where R⁷ is lower alkyl, or
5 wherein R¹ and R² together form =O, =S, or =C(R⁸R⁹) in which R⁸ and R⁹ are independently selected from the group consisting of hydrogen, -CHO, lower alkyl, and cyano, or together form a =CH₂ substituent;

R³ is hydrogen, halogen or lower alkyl, or, when the dotted line at q₁ indicates the presence of a double bond, is CH₂;

10 R⁴ is selected from the group consisting of hydrogen and lower alkyl;

R⁵ is selected from the group consisting of hydrogen, hydroxyl, lower alkyl, lower alkenyl, lower alkoxy, and aryl, or when the dotted line at q₂ indicates the presence of a double bond, is CH₂; and either

X and Y are linked to form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring,
15 if dihydro-oxathiazine, having a substituent R¹⁰ on the carbon atom adjacent to the A ring, wherein R¹⁰ is hydrogen, lower alkyl, lower alkynyl or monocyclic aryl, and Z is hydrogen, or

Y and Z are linked to form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring, if dihydro-oxathiazine, having a substituent R¹⁰ on the carbon atom adjacent to the A ring, wherein R¹⁰ is hydrogen, lower alkyl, lower alkynyl or monocyclic aryl, and X is hydrogen, cyano, lower alkyl,
20 lower alkenyl, lower alkynyl, lower alkoxy, nitro, -COOR¹¹, or -(CH₂)NR¹²R¹³ wherein R¹¹, R¹² and R¹³ are independently hydrogen or lower alkyl,

or a pharmaceutically acceptable salt or ester thereof.

12. A pharmaceutical composition comprising an effective estrone sulfatase inhibiting amount
25 of the compound of any one of claims 1, 2, 3, 6 or 8 in combination with a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International Application No.

PC1/US 98/01846

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07J71/00 A61K31/58

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07J A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 93 05064 A (IMPERIAL COLLEGE) 18 March 1993 cited in the application see the whole document, in particular example 2	1-12
A	US 5 556 847 A (JOHNSON DAVID A ET AL) 17 September 1996 see example 1	1-12

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

18 May 1998

Date of mailing of the international search report

19. 06. 1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Watchorn, P

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 98/01846

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 10,11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PC1/US 98/01846

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HOWARTH N M ET AL: "ESTRONE SULFAMATES: POTENT INHIBITORS OF ESTRONE SULFATASE WITH THERAPEUTIC POTENTIAL" JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 2, 21 January 1994, pages 219-221, XP000652211 cited in the application see page 219, compound 5; page 220, Figure 3</p> <p>-----</p>	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/01846

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9305064 A	18-03-1993	AU 668882 B	23-05-1996
		AU 2490592 A	05-04-1993
		AU 689043 B	19-03-1998
		AU 5837396 A	05-09-1996
		BR 9206434 A	27-09-1994
		CA 2114630 A	18-03-1993
		CZ 9400440 A	18-01-1995
		EP 0641355 A	08-03-1995
		FI 940903 A	20-04-1994
		HU 66097 A	28-09-1994
		JP 7501515 T	16-02-1995
		NO 940635 A	29-04-1994
		SK 24694 A	09-11-1994
		US 5616574 A	01-04-1997

US 5556847 A	17-09-1996	NONE	
